Skip to content

Study · Not a test of the peptide alone · 2024

1 result

Exploring the Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Genitourinary Toxicities in Prostate Cancer Patients Undergoing Radiation Therapy: A Case Study and Discussion.

Andrianu K, Works D, Christiansen A, Enke C, Chaiken L, Baine M

Practical radiation oncology16 May 2024Cited by 2 (Europe PMC)

PMID38752974 (opens in a new tab)DOI10.1016/j.prro.2024.04.006 (opens in a new tab)PepBankPUB-38752974
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with prostate cancer and radiation-induced hemorrhagic cystitis, urinary symptoms improved after empagliflozin was stopped and semaglutide was started.

    In plain wordsIn one man, urinary symptoms improved after he stopped one diabetes drug and started another. The case cannot show which change helped.

    Peptide
    Semaglutide
    Outcome
    DecreaseUrinary symptoms after switch
    Study

    n = 1

    Outcome group
    Urinary continence and bladder function · Kidney and urinary

    Source sentences

    Summary
    After cessation of Jardiance and initiation of semaglutide (GLP-1 agonist), his urinary symptoms significantly improved.
    1 context sentence
    Summary · context
    We herein describe the case of a 65-year-old man with a past medical history of type-2 diabetes mellitus who experienced hemorrhagic cystitis for months following his radiation therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.